In addition to RNAseq, whole-exome sequencing (WES) was performed using molecular barcoding in paired diagnostic-MRD leukaemic cells from 14 patients (6 of them having paired RNAseq and WES data) (Table S1), all of whom achieving CR/MRD+ (Figure 1A). Among the 1346 mutations that either became undetectable or present at MRD, recurrence in 3 or more patients was observed in 48 genes and time points exclusivity were observed in 20 genes (Figure S3). Differential gene expression analysis was performed in I R i using DESeq2 (Methods S1).[12] There was only one gene ( I PIEZO2 i ) differentially expressed between leukaemic cells at diagnosis versus after treatment in patients achieving PR. By contrast, there were 117 differentially expressed genes (adj I p i <0.05, log2FoldChange > |2|) between leukaemic cells at diagnosis vs after treatment in CR/MRD+ patients (Figure S2, Table S2). [Extracted from the article]